Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-Naïve Patients with Hypertension: Tissue-Doppler Imaging Study

Hypertension

Volumn 65, Issue 6, 2015, Pages 1231-1237

  Catena, Cristiana ^a   Verheyen, Nicolas ^a   Pilz, Stefan ^a   Kraigher Krainer, Elisabeth ^a,b   Tomaschitz, Andreas ^a   Sechi, Leonardo A ^c   Pieske, Burkert ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

echocardiography; hypertrophy, left ventricular; renin

Indexed keywords

ALDOSTERONE; RENIN;

ADULT; ALCOHOL CONSUMPTION; ALDOSTERONE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DIET; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR MASS INDEX; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; ALDOSTERONE; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84937539052     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05285     Document Type: Article

References (30)

1. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, Döring A, Broeckel U, Riegger G, Schunkert H. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J. 2003;24:320-328.
2. Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, Goetze JP, Jensen JS. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation. 2009;119:2679-2685. doi: 10.1161/CIRCULATIONAHA.108.793471.
3. Wood P, Piran S, Liu PP. Diastolic heart failure: progress, treatment challenges, and prevention. Can J Cardiol. 2011;27:302-310. doi: 10.1016/j. cjca.2011.02.008.
4. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102:1788-1794.
5. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, Hoffmann W, Poller W, Schultheiss HP, Pauschinger M, Tschöpe C. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation. 2007;116:637-647. doi: 10.1161/CIRCULATIONAHA.106.661983.
6. Bess RL, Khan S, Rosman HS, Cohen GI, Allebban Z, Gardin JM. Technical aspects of diastology: why mitral inflow and tissue Doppler imaging are the preferred parameters? Echocardiography. 2006;23:332-339. doi: 10.1111/j.1540-8175.2006.00215.x.
7. Funder JW. Is aldosterone bad for the heart? Trends Endocrinol Metab. 2004;15:139-142. doi: 10.1016/j.tem.2004.03.006.
8. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266-272. doi: 10.1016/j.mce.2011.06.038.
9. Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res. 2012;44:181-187. doi: 10.1055/s-0031-1291318.
10. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-263. doi: 10.1161/HYPERTENSIONAHA.114.04488.
11. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27.
12. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911-918. doi: 10.1161/HYPERTENSIONAHA.107.095448.
13. Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y. Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res. 2002;25:49-56.
14. Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, Oparil S, DellItalia SJ, Calhoun DA, Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens. 2015;29:241-246. doi:10.1038/jhh.2014.83.
15. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110:558-565. doi: 10.1161/01.CIR.0000138680.89536.A9.
16. Edelmann F, Wachter R, Schmidt AG, et al; Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781-791. doi: 10.1001/jama.2013.905.
17. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. doi: 10.1056/NEJMoa1313731.
18. Catuzzo B, Ciancamerla F, Bobbio M, Longo M, Trevi GP. In patients with severe systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern. J Card Fail. 2003;9:303-310. doi: 10.1054/jcaf.2003.44.
19. Ginelli P, Bella JN. Treatment of diastolic dysfunction in hypertension. Nutr Metab Cardiovasc Dis. 2012;22:613-618. doi: 10.1016/j. numecd.2012.04.016.
20. Mancia G, De Backer G, Dominiczak A, et al; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762. doi: 10.1097/HJH.0b013e3282f0580f.
21. Catena C, Zingaro L, Casaccio D, Sechi LA. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. Am J Med. 2000;109:556-561.
22. Catena C, Novello M, Dotto L, De Marchi S, Sechi LA. Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage. J Hypertens. 2003;21:281-288. doi: 10.1097/01.hjh.0000052436.12292.26.
23. Catena C, Colussi G, Martinis F, Pezzutto F, Sechi LA. Plasma glucose levels and left ventricular diastolic function in nondiabetic hypertensive patients. Am J Hypertens. 2013;26:1353-1361. doi: 10.1093/ajh/hpt114.
24. Catena C, Colussi G, Fedrizzi S, Sechi LA. Association of a prothrombotic state with left-ventricular diastolic dysfunction in hypertension: a tissue-Doppler imaging study. J Hypertens. 2013;31:2077-2084. doi: 10.1097/HJH.0b013e328362d951.
25. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Agabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension. 2008;52:529-534. doi: 10.1161/HYPERTENSIONAHA.108.114140.
26. Marzano L, Colussi G, Sechi LA, Catena C. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. Am J Hypertens. 2015;28:312-318. doi: 10.1093/ajh/hpu154.
27. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838. doi: 10.1161/01. CIR.0000091405.00772.6E.
28. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De Angelis N, Morineau G, dEstienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthasetransgenic mice. Circulation. 2004;110:1819-1825. doi: 10.1161/01.CIR.0000142858.44680.27.
29. Habibi J, DeMarco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell AT, Sowers JR. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol. 2011;300:H1484-H1491. doi: 10.1152/ajpheart.01000.2010.
30. Grandi AM, Imperiale D, Santillo R, Barlocco E, Bertolini A, Guasti L, Venco A. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension. 2002;40:647-652.